A panel of experts in the management of myeloproliferative neoplasms provides a lively discussion on current and emerging treatment options for patients with primary myelofibrosis or polycythemia vera.
EP. 1: Diagnosis and Prognosis of Primary Myelofibrosis
A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.
EP. 2: Therapeutic Decision-Making for Primary Myelofibrosis
Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.
EP. 3: Recent Updates to NCCN Guidelines on MF Treatment
Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.
EP. 4: Monitoring Disease Response or Progression in MF
An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.
EP. 5: Ruxolitinib for Patients With Primary Myelofibrosis
MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.
EP. 6: Fedratinib for Patients With Primary Myelofibrosis
Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.
EP. 7: Bone Marrow Transplant for Patients With MF
Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.